Homepage | Lupus Science & Medicine
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
About | Lupus Science & Medicine
Lupus Science & Medicine®is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. The journal publishes research on lupus from fields including, but not limited to: rheumatology, dermatology, …
Disease-modifying therapies in systemic lupus erythematosus for ...
May 21, 2024 · Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression’. The objective of this review was to classify current SLE treatments according to the proposed non-renal disease modification criteria excluding toxicities ...
31 SLE-DAS | Lupus Science & Medicine
The systemic lupus erythematosus Disease Activity Score (SLE-DAS) aims to provide a practical, accurate, and sensitive to change tool to measure the activity of SLE. 1 This new tool addresses the pitfalls of the previously available instruments. The SLE-DAS is useful in routine clinical practice to quantify global disease activity. It enables …
Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou ,1 Judith A James,1,2 Cristina Arriens ,1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 Anca Askanase3
ABSTRACT Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment- associated toxicities and slowing or preventing organ damage progression’. The objective of this review was to classify current SLE treatments according to the proposed non- renal disease modification criteria excluding ...
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
29 Lupus and the bones | Lupus Science & Medicine
Sep 4, 2024 · Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As survival has improved, this has also led to long-term conditions being more prevalent, including osteoporosis and the risk of fractures.Prevalence of osteoporosis is increased in SLE patients. In cohort ...
20 Diagnosis and treatment of neuropsychiatric lupus
Aug 31, 2020 · Neuropsychiatric (NP) involvement is one of the most complex and challenging features of systemic lupus erythematosus (SLE) encompassing the central (CNS), peripheral (PNS) and autonomous nervous system (ANS) as defined by the 1999 American College of Rheumatology standard nomenclature and case definitions. NPSLE has a negative impact on patient’s quality of life and is associated with ...
02 Lupus and cancer | Lupus Science & Medicine
Malignancy risk in systemic lupus erythematosus (SLE) is about 15% higher than the general age-and-sex-matched population. Hematologic cancers, especially B-cell lymphomas, are about three-fold increased in SLE, while breast, uterine, ovarian, and prostate cancer are associated with lower risk. 1 2Increased susceptibility to both SLE and malignancy could result from genetic variations that ...